You're using an outdated browser. To get the most out of this website, as well as many others, please consider upgrading to a modern browser, such as Google Chrome, Mozilla Firefox, or Microsoft Edge.

Open menu


Glaucoma therapy Roclanda launched by Santen

The therapy is a fixed-dose combination (FDC) of both netarsudil and latanoprost, and is a novel Rho-kinase (ROCK) inhibitor, which reduces intraocular pressure (IOP). The treatments also target trabecular meshwork (TM) dysfunction.